TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01603914

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: central venous catheter replacement (Arrowgard Blue plus Quad-Lumen CVC )
Description: Routine practices for the type of catheter of each participating Unit will be respected. Multilumen central venous catheter will be used (i.e Arrowgard Blue plus Quad-Lumen CVC set). Impregnated Catheter with antiseptics or with antibiotics will be allowed.The anatomical locations selected for the replacement of central venous catheter are: subclavian vein, internal jugular vein, femoral vein and the change will be addressed according to the randomization.~The dressing and maintenance of the catheter will be guided according with the Guides of The Centers for Disease Control and Prevention (CDCs) and a check-in lists will be fill in for each catheter.~A pre-defined stratified analysis will be performed according with: type of catheter, participating unit, and insertion site.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: central venous catheter replacement (Arrowgard Blue plus Quad-Lumen CVC )
Description: Routine practices for the type of catheter of each participating Unit will be respected. Multilumen central venous catheter will be used (i.e Arrowgard Blue plus Quad-Lumen CVC set). Impregnated Catheter with antiseptics or with antibiotics will be allowed.The anatomical locations selected for the replacement of central venous catheter are: subclavian vein, internal jugular vein, femoral vein and the change will be addressed according to the randomization.~The dressing and maintenance of the catheter will be guided according with the Guides of The Centers for Disease Control and Prevention (CDCs) and a check-in lists will be fill in for each catheter.~A pre-defined stratified analysis will be performed according with: type of catheter, participating unit, and insertion site.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: central venous catheter replacement (Arrowgard Blue plus Quad-Lumen CVC )
Description: Routine practices for the type of catheter of each participating Unit will be respected. Multilumen central venous catheter will be used (i.e Arrowgard Blue plus Quad-Lumen CVC set). Impregnated Catheter with antiseptics or with antibiotics will be allowed.The anatomical locations selected for the replacement of central venous catheter are: subclavian vein, internal jugular vein, femoral vein and the change will be addressed according to the randomization.~The dressing and maintenance of the catheter will be guided according with the Guides of The Centers for Disease Control and Prevention (CDCs) and a check-in lists will be fill in for each catheter.~A pre-defined stratified analysis will be performed according with: type of catheter, participating unit, and insertion site.
Study: NCT00959452

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy
Description: 16 sessions vs 5 sessions of cognitive behavioural therapy
Study: NCT03885388

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MTX
Description: multicourse methotrexate chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTX+ACTD
Description: combination use of methotrexate and actinomycin
Study: NCT02234180

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: Given PO
Study: NCT00746161

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Reconstruction after total gastrectomy
Description: Roux-en-Y

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reconstruction after total gastrectomy
Description: double tract reconstruction
Study: NCT00815737

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhubarb
Description: 14 days of rhubarb

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 14 days of Placebo
Study: NCT00848315

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Intervention
Description: The intervention emphasizes patients' ethnic preferences and traditions (e.g., adapting ethnic recipes to meet dietary goals) and the use of available community resources (e.g., available areas for exercise), and is delivered utilizing strategies and materials appropriate for low-literate/illiterate patients.
Study: NCT02112591

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transobturator subtrigonal tape S-TOT
Description: Minimally invasive surgery for placement of suburethral polypropylene tape (TOT), which is widely used around the world and considered the standard of treatment at present, has very limited efficacy when considering the correction of SUI without affecting normal micturition. There is evidence that the placement of autologous fascia tape in subtrigonal position has higher efficacy. Thus, the subtrigonal placement of polypropylene mesh tape through minimally invasive procedures could have higher efficacy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transobturator suburethral tape (TOT)
Description: Minimally invasive procedures in which needles are inserted via transobturator approach for the placement in mid-urethral position of polypropylene tape that is 1.5cm wide for the treatment of SUI
Study: NCT04120324

Intervention type: OTHER
Intervention: Eligible for Same Day Discharge
Description: Preoperative Physiotherapy and Anesthesia Criteria met.

Intervention type: OTHER
Intervention: Eligible for Same Day Discharge
Description: Preoperative Physiotherapy and Anesthesia Criteria met.

Intervention type: PROCEDURE
Intervention: Primary Single Joint Total Hip Arthroplasty
Description: Total Hip Replacement Surgery

Intervention type: PROCEDURE
Intervention: Primary Single Joint Total Hip Arthroplasty
Description: Total Hip Replacement Surgery

Intervention type: PROCEDURE
Intervention: Primary Single Joint Total Hip Arthroplasty
Description: Total Hip Replacement Surgery

Intervention type: OTHER
Intervention: Discharge Same Day
Description: Postoperative criteria for Same Day Discharge met.
Study: NCT01635140

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy
Description: A total dose of 39 Gy in daily fractions of 3 Gy, 5 Fractions per week

Intervention type: RADIATION
Group type: OTHER
Intervention: Conventional arm
Description: A total dose of 54 Gy in 30 fractions giving 1.8 Gy per fraction.
Study: NCT04051580

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactated Ringer
Description: Comparison of Lactated Ringer's Solution and PlasmaLyte-A as a Base Solution for Del Nido Cardioplegia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactated Ringer
Description: Comparison of Lactated Ringer's Solution and PlasmaLyte-A as a Base Solution for Del Nido Cardioplegia
Study: NCT00407667

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial galvanic stimulation
Description: for tDCS: Siemens Universal-Neuroton 826 for arm training: Bi-Manu-Track, Reha-Stim, Berlin

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial galvanic stimulation
Description: for tDCS: Siemens Universal-Neuroton 826 for arm training: Bi-Manu-Track, Reha-Stim, Berlin

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial galvanic stimulation
Description: for tDCS: Siemens Universal-Neuroton 826 for arm training: Bi-Manu-Track, Reha-Stim, Berlin
Study: NCT03608969

Intervention type: OTHER
Intervention: NOT-S
Description: Participants are assessed for the orofacial function using the Nordic Orofacial test- screening (NOT-S), Gross Motor Function Classification System (GMFCS), Manual Ability Classification System (MACS) and Communication Function Scale (CFS). Oral health related quality of life is assessed using the Parental- Caregiver Perceptions Questionnaire (P-CPQ). Caries experience was measured by identifying decayed, missing, and filled teeth for deciduous and permanent teeth (dmft). Gingival index and type of occlusion will be recorded.
Study: NCT00940173

Intervention type: DEVICE
Group type: OTHER
Intervention: DIABECELL(R)
Description: 10,000 IEQ/kg injected into the peritoneal cavity via laparoscopy

Intervention type: DEVICE
Group type: OTHER
Intervention: DIABECELL(R)
Description: 15,000 IEQ/kg injected into the peritoneal cavity via laparoscopy

Intervention type: DEVICE
Group type: OTHER
Intervention: DIABECELL(R)
Description: 20,000 IEQ/kg injected into the peritoneal cavity via laparoscopy

Intervention type: DEVICE
Group type: OTHER
Intervention: DIABECELL(R)
Description: 5,000 IEQ/kg injected into the peritoneal cavity via laparoscopy
Study: NCT02080078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Theophylline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Theophylline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Study: NCT02421510

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotagliflozin
Description: High dose Sotagliflozin, once daily, before the first meal of the day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sotagliflozin
Description: Low dose Sotagliflozin,once daily, before the first meal of the day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, once daily, before the first meal of the day
Study: NCT02448043

Intervention type: DRUG
Group type: OTHER
Intervention: Bimatoprost 0.01%
Description: Bimatoprost drops added to the proximal nail folds of the randomized study hand digits two times per day for 30 days

Intervention type: DRUG
Group type: OTHER
Intervention: Bimatoprost 0.01%
Description: Bimatoprost drops added to the proximal nail folds of the randomized study hand digits two times per day for 30 days

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo: saline
Description: Placebo drops added to the proximal nail folds of the hand digits opposite the study hand two times per day for 30 days

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo: saline
Description: Placebo drops added to the proximal nail folds of the hand digits opposite the study hand two times per day for 30 days
Study: NCT01138046

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib in combination with weekly paclitaxel
Description: These subjects will receive weekly paclitaxel (80 mg/m2 IV for 3 weeks in a 4 week cycle) plus lapatinib (1500 mg once daily, starting on the second day of phase I). Subjects will receive a daily dose of lapatinib until disease progression or withdrawal from study treatment due to unacceptable toxicity or withdrawal of consent. Study completion is defined as deaths after administering study treatment for more than once. Subjects will be treated with paclitaxel for standard of 6 cycles, and may be continued at the discretion of investigators. If the subject experiences progression, an unacceptable toxicity related to paclitaxel, or termination of lapatinib therapy, paclitaxel therapy must be terminated any time of study period, even before 6 cycles of paclitaxel are given.
Study: NCT00850642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2190195 100mg
Description: GSK2190915 is a high affinity 5-lipoxygenase-activating protein (FLAP) inhibitor.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo :~2% (w/w) Ethanol, sucralose (5 mg/100 mL of oral solution) to 100 % (w/w) aqueous sodium carbonate buffer (0.010 M, pH 9-10)
Study: NCT04314089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GT103
Description: intravenously (dose depending)
Study: NCT00827242

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Following a 4-week placebo lead-in period, subjects received placebo tablet by mouth once daily over a 12-week period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tadalafil
Description: Following a 4-week placebo lead-in period, subjects received tadalafil 5 mg tablet by mouth once daily over a 12-week period.
Study: NCT02650557

Intervention type: PROCEDURE
Intervention: angiography
Description: angiography or arteriography is a medical imaging technique used to visualize the inside, or lumen, of blood vessels and organs of the body, with particular interest in the arteries, veins, and the heart chambers. This is traditionally done by injecting a radio-opaque contrast agent into the blood vessel and imaging using X-ray based techniques such as fluoroscopy.

Intervention type: PROCEDURE
Intervention: angiography
Description: angiography or arteriography is a medical imaging technique used to visualize the inside, or lumen, of blood vessels and organs of the body, with particular interest in the arteries, veins, and the heart chambers. This is traditionally done by injecting a radio-opaque contrast agent into the blood vessel and imaging using X-ray based techniques such as fluoroscopy.
Study: NCT03637374

Intervention type: DEVICE
Group type: OTHER
Intervention: Visceral Manifold and Thoracic Bifurcation
Description: Endovascular stent graft system
Study: NCT02316275

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No post-operative activity restrictions
Description: Patients are to resume regular activity immediately after mid-urethral sling surgery. The investigators will determine the impact of unrestricted post-operative activity on continence outcomes of mid-urethral sling surgery in women with stress urinary incontinence (SUI). Investigators will measure the effect of unrestricted post-operative activity on early health-related quality of life (HRQOL). A Productivity Loss form for cost-effective analysis will be asked of the patient.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard post-operative activity restriction
Study: NCT04478643

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic: Lactobacillus Reuteri
Description: Lactobacillus reuteri ATCC PTA 5289 (a minimum of 2 × 108 colony-forming units L. reuteri Prodentis/lozenge, BioGaia AB)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo lozenge. Will be identical in taste, texture and appearance to the Probiotic one.
Study: NCT03637374

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Visceral Manifold and Thoracic Bifurcation
Description: Endovascular stent graft system

Intervention type: DEVICE
Group type: OTHER
Intervention: Unitary Manifold
Description: Endovascular stent graft system

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Unitary Manifold
Description: Endovascular stent graft system

Intervention type: DEVICE
Group type: OTHER
Intervention: TAAA Debranching Stent Graft System
Description: Endovascular stent graft system
Study: NCT01158183

Intervention type: DRUG
Intervention: BAY86-5046_Interferon-beta-1b
Description: Electronic questionnaires
Study: NCT03637374

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TAAA Debranching Stent Graft System
Description: Endovascular stent graft system
Study: NCT03595891

Intervention type: OTHER
Intervention: Non-Interventional
Description: Non-Interventional

Intervention type: OTHER
Intervention: Non-Interventional
Description: Non-Interventional
Study: NCT03947723

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation
Description: The eyelid segments to be excised as part of their planned lateral tarsal strip procedure will be marked and divided into 4 equal sections (2 sections on each lid). A corneal shield will be placed into the fornix prior to treatment. Each section will be treated with the designated power setting in the following manner. The probe will be inserted into the follicle under direct visualization to a depth of approximately 1.4 mm. The designated power will be applied for 1 second. All lashes in each segment will be treated. The segments will then be excised and placed into labelled and coded containers of formalin.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation
Description: The eyelid segments to be excised as part of their planned lateral tarsal strip procedure will be marked and divided into 4 equal sections (2 sections on each lid). A corneal shield will be placed into the fornix prior to treatment. Each section will be treated with the designated power setting in the following manner. The probe will be inserted into the follicle under direct visualization to a depth of approximately 1.4 mm. The designated power will be applied for 1 second. All lashes in each segment will be treated. The segments will then be excised and placed into labelled and coded containers of formalin.
Study: NCT03503123

Intervention type: DEVICE
Intervention: Monitoring physiology with Electrical Impedance Tomography, Electromyography and transcutaneous carbon dioxide measurements.
Description: Both groups get the same exposures: with measure physiology in both groups by using non-invasive measurement techniques. The techniques we use are Electrical Impedance Tomography to determine degree of hyperinflation. We use Electromyography to analyse respiratory drive. We measure transcutaneous carbon dioxide to assess the effects of non-invasive ventilation. Thereby, we will perform lung function tests.
Study: NCT02828267

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Negotiational Intervention
Description: This is a 5-10 minute conversation using the principles of motivational interviewing between the healthcare practioner and the patient to motivate the patient to identify at risk alcohol use and through self-empowerment create a plan to decrease alcohol use.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Negotiational Intervention
Description: This is a 5-10 minute conversation using the principles of motivational interviewing between the healthcare practioner and the patient to motivate the patient to identify at risk alcohol use and through self-empowerment create a plan to decrease alcohol use.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Negotiational Intervention
Description: This is a 5-10 minute conversation using the principles of motivational interviewing between the healthcare practioner and the patient to motivate the patient to identify at risk alcohol use and through self-empowerment create a plan to decrease alcohol use.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Booster
Description: This SMS based intervention will be a text to the participant once weekly including motivational statements to try to have patients reduce their alcohol use.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Personalized Booster
Description: This SMS based intervention will be a text to the participant once weekly including motivational statements to try to have patients reduce their alcohol use. Information in this text will be personalized based on the participants specific reasons for reducing their alcohol use rather than a standard text content.
Study: NCT01403298

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family-Based HIV prevention
Description: This individual, family-based intervention provides sex and HIV/AIDS education as part of a family-based general health education program that focuses on safe decision-making and how to control emotions to stay safe and improve parenting skills.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Adolescent Only Health Promotion
Description: An individual, adolescent-only health education program that focuses on risk behaviors related to HIV/AIDS, smoking, diet and exercise
Study: NCT04415515

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RN Standard care coordination and disease management
Description: RN Standard care coordination and disease management
Study: NCT01727180

Intervention type: OTHER
Intervention: Questionnaire based on the McGill Pain Questionnaire
Description: Interview questionnaire based on the short form of the McGill Pain Questionnaire
Study: NCT01104025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG, rabbit
Description: ATG, rabbit (Thymoglobulin, Genzyme) will be dosed at 5 mg/kg/dose, given IV on 5 consecutive days (titrated over 4 to 8 hours).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide will be dosed at 150mg/m2, given IV. The first dose will be given 7 days (+/- 2 days) after the first dose of ATG, and be given weekly for a total of 7 doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Intrathecal Methotrexate and hydrocortisone will be administered to CNS+ patients (CNS+ patients are those patients which have any of the following: elevated CSF (cerebral spinal fluid) protein or white count, seizures, focal or global neurologic deficit, MRI abnormalities consistent with CNS involvement by HLH.) in the following doses: age\< 1 yr: 6/8mg (MTX/HC), 1-2 yrs: 8/10mg, 2-3 yrs: 10/12mg, \>3 yrs: 12/15 mg. It will be administered (+/- 3 days) on day 7, 14, 21 and 42.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hydrocortisone
Description: Intrathecal Methotrexate and hydrocortisone will be administered to CNS+ patients (CNS+ patients are those patients which have any of the following: elevated CSF (cerebral spinal fluid) protein or white count, seizures, focal or global neurologic deficit, MRI abnormalities consistent with CNS involvement by HLH.) in the following doses: age\< 1 yr: 6/8mg (MTX/HC), 1-2 yrs: 8/10mg, 2-3 yrs: 10/12mg, \>3 yrs: 12/15 mg. It will be administered (+/- 3 days) on day 7, 14, 21 and 42.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: will be started with the ATG. It will be divided BID, given IV for at least 1 week before switching to PO. Dosing: 20mg/m2/day x7days, 10mg/m2/day x7days, 5mg/m2/day x14days, 2.5mg/m2/day x14days, 1.25mg/m2/day x14days.
Study: NCT01196572

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Internal Urethrotomy
Description: surgical incision of urethral stricture using endoscopic cold knife vs. endoscopic laser

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Internal Urethrotomy
Description: surgical incision of urethral stricture using endoscopic cold knife vs. endoscopic laser
Study: NCT03756441

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation
Description: This intervention is a meditative practice which the individuals will practive in their daily life following the MBHP protocol

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychotherapy group
Description: Caregivers will learn the technique of group problem solving
Study: NCT04071652

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mistral implantation
Description: Mistral implant is implanted in the Tricuspid valve
Study: NCT02334644

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic Formula (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175)
Description: 2 sachets/day x 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 sachets/day x 12 weeks